Are these struggling stocks set for a comeback? Currently offering discounts of up to -42%.
In the troubled waters of the S&P 500, a few stocks are kicking up a storm. With the economic whirlwind stirring up some ugly seas, certain stocks are taking a beating this 2025. But could this stormy start present a golden opportunity for savvy investors? Let's take a look at two troubled titans: Deckers Outdoor and Moderna.
Deckers Outdoor: The Sinking Ship?
When it comes to losers in the S&P 500, no one sinks lower than Deckers Outdoor. With a disheartening year-to-date loss of 42%, Deckers Outdoor is the name on everyone's lips and the footwear company's stock is sitting at the bottom of the index, despite a robust 17% increase in revenue in the last quarter of the previous year. Analysts, however, aren't impressed, and investors have associated the footwear business with the current economic climate. And with Trump's new tariffs looming on the horizon, the future doesn't look too promising either. The tariffs could put the final nail in the coffin for Deckers Outdoor's projections. While the stock is cheaper than it was a few months ago, it might be best to steer clear of this sinking ship — for now. But to heed the old nautical saying, "A ship in the harbor is safe, but that's not what ships are built for." Investors should keep a watchful eye on Deckers Outdoor, just in case.
Trying to spot some hope for turnaround candidates? Check out the Reversal Index from BÖRSE ONLINE.
Moderna: Rocky Shores Ahead?
Docked not too far ahead (or behind) Deckers Outdoor, Moderna has sailed right into the second-to-last spot on the S&P 500. The stock has been battered, losing 34% since the beginning of the year, much like its German counterpart BioNTech, due to the plummeting demand for COVID-19 vaccines. The stock has now returned to its pre-pandemic level, but will it set sail on calmer seas or will the journey continue to be rocky?
Despite the choppy waters, investors might still want to hold onto Moderna's stock. The company's innovative mRNA technology, which has proven successful with COVID-19, could soon be a game-changer for the treatment of cancer. The first medications are expected to hit the market in the coming years. As for the western population, the demographic trends suggest a growing demand for such treatments. In the short and medium term, though, it's going to be a bumpy ride for Moderna's stock. U.S. Health Minister Robert F. Kennedy, known for his opposition to vaccinations, recently recommended vitamin A as a remedy for measles, which could create more turbulence in the waters.
In other headlines: Is it time to ditch Tesla's stock? Or maybe it's time to dive headfirst into the world of cryptocurrencies?
Conflict of Interest Note: The price of the financial instruments is based on an index as the underlying. Boersenmedien AG has developed this index and holds the rights to it. Boersenmedien AG has signed a cooperation agreement with the issuer of the displayed securities, granting the issuer a license to use the index in return for remuneration from the issuer.
Insights from Enrichment Data:
Moderna (NASDAQ: MRNA)
- Moderna has seen a significant net loss of $3.6 billion in 2024
- Revenue in 2024 was down 53% compared to the prior year
- Analysts maintain a “Hold” rating with nearly 98% upside potential
- Clinical progress into new treatments could spur recovery
- A potential market catalyst in early May 2025 could spark increased investor interest
Deckers Outdoor (NASDAQ: DECK)
- Deckers Outdoor is one of the top 33 stocks with the potential to rally 50% or more in 2025
- Analysts recommend a “Buy” rating based on valuation and growth prospects
- A broader market rally could benefit Deckers Outdoor
- Lower prices might represent a buying opportunity, especially during a market recovery or a "summer panic" rally
- Deckers Outdoor, despite bearing the title of the biggest loser in the S&P 500 with a year-to-date loss of 42%, has shown a robust 17% increase in revenue in the last quarter of the previous year.
- Despite analysts not being impressed with Deckers Outdoor's performance, certain investors see the current economic climate and the stock's lower price tag as an opportunity for investment, with Trump's new tariffs being the main concern for the footwear company's future.
- On the other hand, Moderna, another troubled titan in the S&P 500, has lost 34% since the beginning of the year, following the plummeting demand for COVID-19 vaccines.
- However, Moderna's innovative mRNA technology, which has proven successful in developing COVID-19 vaccines, could soon find application in cancer treatments, with the first medications expected to hit the market in the coming years, potentially offering a promising turnaround for the stock.
